Key Points from Freenome’s Announcement on PREEMPT CRC®:
- The PREEMPT CRC® study successfully met all primary endpoints, including a 79.2% sensitivity for colorectal cancer (CRC) and a 91.5% specificity for non-advanced colorectal neoplasia.
- The study, being the largest of its kind for a blood-based CRC test, enrolled 48,995 participants, reflecting the diversity of average-risk adults in the U.S.
- Freenome intends to continue optimizing the test in 2024 for improved CRC sensitivity and advanced adenoma (AA) detection, aiming to meet guideline and policy milestones.
- The blood test showed 79.2% sensitivity in detecting CRC across various stages and 91.5% specificity for non-advanced colorectal neoplasia. It also demonstrated 12.5% sensitivity in detecting advanced adenomas.